BUZZ-Exagen falls after stock sale launch

Reuters

May 08

BUZZ-<a href="https://laohu8.com/S/XGN">Exagen</a> falls after stock sale launch

** Shares of diagnostic test maker Exagen XGN.O down 16.8% post-market to $5.68 on equity offering news

** Vista, California-based co commences stock offering with Canaccord Genuity as sole bookrunner; deal size not disclosed

** It intends to use net proceeds for working capital, general purposes, and potentially acquire, in-license or invest in complementary technologies or business, per the SEC prospectus filing

** Co, which makes testing products that help in diagnosing auto-immune diseases such as rheumatism, has ~18 mln shares outstanding for ~$123 mln market cap

** Stock on Weds closed up 6.4% at $6.83, extending YTD gain to ~67%

(Lance Tupper is a Reuters market analyst. The views expressed are his own)

((lance.tupper@tr.com 1-646-279-6380))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2533848964"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2533848964\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2533848964?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-08 04:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2533848964","market":"us","top_or_hot":-1,"title":"BUZZ-Exagen falls after stock sale launch","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/XGN\">Exagen</a> falls after stock sale launch</title></head><body><p>**  Shares of diagnostic test maker Exagen <span>XGN.O</span> down 16.8% post-market to $5.68 on equity offering news</p><p>** Vista, California-based co commences stock offering with Canaccord Genuity as sole bookrunner; deal size not disclosed</p><p>** It intends to use net proceeds for working capital, general purposes, and potentially acquire, in-license or invest in complementary technologies or business, per the SEC prospectus filing</p><p>** Co, which makes testing products that help in diagnosing auto-immune diseases such as rheumatism, has ~18 mln shares outstanding for ~$123 mln market cap</p><p>** Stock on Weds closed up 6.4% at $6.83, extending YTD gain to ~67%</p><p>(Lance Tupper is a Reuters market analyst. The views expressed are his own)</p><p>((lance.tupper@tr.com 1-646-279-6380))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Exagen falls after stock sale launch</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Exagen falls after stock sale launch\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-08 04:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/XGN\">Exagen</a> falls after stock sale launch</title></head><body><p>**  Shares of diagnostic test maker Exagen <span>XGN.O</span> down 16.8% post-market to $5.68 on equity offering news</p><p>** Vista, California-based co commences stock offering with Canaccord Genuity as sole bookrunner; deal size not disclosed</p><p>** It intends to use net proceeds for working capital, general purposes, and potentially acquire, in-license or invest in complementary technologies or business, per the SEC prospectus filing</p><p>** Co, which makes testing products that help in diagnosing auto-immune diseases such as rheumatism, has ~18 mln shares outstanding for ~$123 mln market cap</p><p>** Stock on Weds closed up 6.4% at $6.83, extending YTD gain to ~67%</p><p>(Lance Tupper is a Reuters market analyst. The views expressed are his own)</p><p>((lance.tupper@tr.com 1-646-279-6380))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"XGN","symbol_name":"Exagen","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250507:nL6N3RF0R8:1","article_id":"2533848964","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2533848964","pubTimestamp":1746650270,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Exagen falls after stock sale launch**  Shares of diagnostic test maker Exagen XGN.O down 16.8% post-market to $5.68 on equity offering news** Vista, California-based co commences stock offering with Canaccord Genuity as sole bookrunner; deal size not disclosed** It intends to use net proceeds for working capital, general purposes, and potentially acquire, in-license or invest in complementary technologies or business, per the SEC prospectus filing** Co, which makes testing products that help in diagnosing auto-immune diseases such as rheumatism, has ~18 mln shares outstanding for ~$123 mln market cap** Stock on Weds closed up 6.4% at $6.83, extending YTD gain to ~67%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"XGN":"Exagen","BK4139":"生物科技"},"translate_title":"BUZZ-Exagen股票发售后下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XGN":0.9},"content_text":"BUZZ-Exagen falls after stock sale launch**  Shares of diagnostic test maker Exagen XGN.O down 16.8% post-market to $5.68 on equity offering news** Vista, California-based co commences stock offering with Canaccord Genuity as sole bookrunner; deal size not disclosed** It intends to use net proceeds for working capital, general purposes, and potentially acquire, in-license or invest in complementary technologies or business, per the SEC prospectus filing** Co, which makes testing products that help in diagnosing auto-immune diseases such as rheumatism, has ~18 mln shares outstanding for ~$123 mln market cap** Stock on Weds closed up 6.4% at $6.83, extending YTD gain to ~67%(Lance Tupper is a Reuters market analyst. The views expressed are his own)((lance.tupper@tr.com 1-646-279-6380))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}